Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310460 | 0.92 | MEN1 (0.57) | GPR119KMT2ATGFBR1MEN1MAPT | |
| SCHEMBL4309355 | 0.92 | MEN1 (0.57) | GPR119KMT2ATGFBR1MEN1MAPT | |
| SCHEMBL4306235 | 0.91 | MEN1 (0.53) | GPR119KMT2ATGFBR1MEN1MAPT | |
| SCHEMBL4311345 | 0.91 | KMT2A (0.58) | GPR119TP53KMT2AMEN1JAK2 | |
| SCHEMBL4307751 | 0.91 | KMT2A (0.58) | GPR119TP53KMT2AMEN1JAK2 | |
| SCHEMBL4306650 | 0.89 | MEN1 (0.52) | GPR119TP53KMT2ATGFBR1MEN1 | |
| SCHEMBL4307698 | 0.88 | KMT2A (0.58) | GPR119TP53KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4306735 | 0.88 | KMT2A (0.57) | GPR119TP53KMT2AMEN1JAK2 | |
| SCHEMBL5969609 | 0.87 | CCR5 (0.47) | KMT2AMEN1CYP2C19 | |
| SCHEMBL4312794 | 0.86 | MEN1 (0.62) | GPR119KMT2AMEN1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | claimed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | claimed |
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | disclosed |
| EP-1693061-A1 | Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases | UCB, S.A. (BE) | 2006-08-23 | — | — | EP | disclosed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | disclosed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | PNMT, HTR5A, HTR4 | GPR119 2409/4885TP53 4642/4885KMT2A 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.